Pampisford, United Kingdom
Pampisford, United Kingdom

Time filter

Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE-2009-3-2-01 | Award Amount: 7.90M | Year: 2010

Biodiversity in the seas is only partly explored, although marine organisms are excellent sources for many industrial products. Through close co-operation between industrial and academic partners, the MAREX project will collect, isolate and classify marine organisms, such as micro- and macroalgae, cyanobacteria, sea anemones, tunicates and fish from the Atlantic, Pacific and Indian Oceans as well as from the Mediterranean, Baltic and Arabian Seas. Extracts and purified compounds of these organisms will be studied for several therapeutically and industrially significant biological activities, including anticancer, anti-inflammatory, antiviral and anticoagulant activities by applying a wide variety of screening tools, as well as for ion channel/receptor modulation and plant growth regulation. Chromatographic isolation of bioactive compounds will be followed by structural determination. Sustainable cultivation methods for promising organisms, and biotechnological processes for selected compounds will be developed, as well as biosensors for monitoring the target compounds. The work will entail sustainable organic synthesis of selected active compounds and new derivatives, and development of selected hits to lead compounds. The project will expand marine compound libraries. MAREX innovations will be targeted for industrial product development in order to improve the growth and productivity of European marine biotechnology. MAREX aims at a better understanding of environmentally conscious sourcing of marine biotechnology products and increased public awareness of marine biodiversity and potential. Finally, MAREX is expected to offer novel marine-based lead compounds for European industries and strengthen their product portfolios related to pharmaceutical, nutraceutical, cosmetic, agrochemical, food processing, material and biosensor applications.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2010.2.4.2-3 | Award Amount: 15.68M | Year: 2010

The initiation and perpetuation of atrial fibrillation (AF) can be regarded as a complication of a progressive transformation of the structure and functional properties of the atria. This transformation is the result of complex and multiple changes at the molecular, cellular and organ levels which interact to form the basis for proarrhythmic mechanisms in AF. Numerous individual and environmental factors are probably involved in this profound transformation process in the atria. Therefore, we believe that progress in the diagnostics, prevention and treatment of AF requires highly integrative research from the molecule to bedside and from specific signaling pathways and electrophysiological mechanisms to population based studies. A consortium was formed providing this variety of expertises and has identified central research objectives for improvements in AF prevention and therapy. In 5 work packages focusing on basic research, new biomarkers for AF and therapeutic targets will be identified. We will study mechanisms of conduction disturbances in the atria, explore new ion channel targets for treatment of AF, identify specific alterations in the atria depending on the underlying heart disease, and evaluate beneficial effects of organ-protective compounds. Within two clinically oriented work packages the clinical application of these findings will be tested. The predictive value of diagnostic tools like serum biomarkers, 3D reconstruction of atrial conduction patterns based on high resolution body surface ECGs, and echocardiographic markers will be studied in large scale population studies. The new therapeutic targets will be explored in smaller prove-of-principle clinical trials (substrate oriented ablation, new pharmacological targets, and local gene delivery).


Patent
Xention Ltd | Date: 2014-02-06

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein X_(1), R_(1), R_(2), R_(3), R_(4), and R_(5 )are defined as set forth in the specification. The compounds are useful as potassium ion channel inhibitors.


Patent
Xention Ltd | Date: 2015-05-28

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein X_(1), R_(1), R_(2), R_(3), R_(4), and R_(5 )are defined as set forth in the specification. The compounds are useful as potassium ion channel inhibitors.


The present invention provides compounds of formula (I): (Formula (I); wherein A, R^(1), R^(2), R^(3)_(I), V, X, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by K_(ir)3.1 and/or K_(ir)3.4 or any heteromultimers thereof, or that require inhibition of K_(ir)3.1 and/or K_(ir)3.4 or any heteromultimers thereof.


The present invention provides compounds of formula (I): (Formula (I)); wherein A, R^(1), R^(2), R^(3)_(I), V, X, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by K_(ir)3.1 and/or K_(ir)3.4 or any heteromultimers thereof, or that require inhibition of K_(ir)3.1 and/or K_(ir)3.4 or any heteromultimers thereof.


Patent
Xention Ltd | Date: 2014-06-23

The present invention relates to a structure comprising a biological membrane and a porous or perforated substrate, a biological membrane, a substrate, a high throughput screen, methods for production of the structure membrane and substrate, and a method for screening a large number of test compounds in a short period. More particularly it relates to a structure comprising a biological membrane adhered to a porous or perforated substrate, a biological membrane capable of adhering with high resistance seals to a substrate such as perforated glass and the ability to form sheets having predominantly an ion channel or transporter of interest, a high throughput screen for determining the effect of test compounds on ion channel or transporter activity, methods for manufacture of the structure, membrane and substrate, and a method for monitoring ion channel or transporter activity in a membrane.


Patent
Xention Ltd | Date: 2013-05-02

The present invention relates to a structure comprising a biological membrane and a porous or perforated substrate, a biological membrane, a substrate, a high throughput screen, methods for production of the structure membrane and substrate, and a method for screening a large number of test compounds in a short period. More particularly it relates to a structure comprising a biological membrane adhered to a porous or perforated substrate, a biological membrane capable of adhering with high resistance seals to a substrate such as perforated glass and the ability to form sheets having predominantly an ion channel or transporter of interest, a high throughput screen for determining the effect of test compounds on ion channel or transporter activity, methods for manufacture of the structure, membrane and substrate, and a method for monitoring ion channel or transporter activity in a membrane.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 144.79K | Year: 2014

The discovery of new drugs has become an extremely costly and time-consuming activity, and is associated with many late-stage failures. After 30 years of research there still remains a large unmet need for safe and effective treatments for chornic pain. One of the reasons for so many clinical failures, especially in the area of pain drug discovery, is the difficulty in predicting whether a potential drug will work in man. In order to address this problem we intend to develop a new technique that will allow the detailed evaluation of new drugs in a model pain system and so bridge the gap between traditional and well characterised but simple primary testing assays and more complex whole animal behavioural models. Success in this project will allow us to prioritise new pain drugs for testing in animal models, reducing the unnecessary use of animals as well as accelerating the drug discovery process and improving the chances of achieving success in man.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 143.91K | Year: 2013

Respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are increasing within the global population. The UK has the highest prevalence of asthma in the world, with ~9 million people of all ages and race affected and where 90% of deaths are preventable. 3.2 Million people have COPD and ~23,000 people die from the disease each year, making COPD the UK’s fifth biggest killer disease. This increasing problem is recognised by the introduction of government guidelines recently set up to improve diagnosis and hence initiate earlier treatment of both diseases. However, current drugs are only able to treat the symptoms. As the diseases progress and symptoms get more aggressive, these drugs simply do not provide adequate relief. It is our intention to find a new drug that is superior to the current treatments. Only when such a drug is available can we begin to see an increase in the quality of life to the people affected by these chronic diseases.

Loading Xention Ltd collaborators
Loading Xention Ltd collaborators